We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Evaluation Indexes for Antibody Production in Sera After Immunization

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00964769
First Posted: August 25, 2009
Last Update Posted: August 25, 2009
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Ewha Womans University
  Purpose
The aim of this study is to evaluate analytical methods such as ELISA and OPKA that measure the activity of vaccine-induced pneumococcal antibodies. After validation of ELISA and OPKA, pneumococcal antibodies were measured by ELISA and OPKA in paired samples before and after immunization (pneumococcal PS vaccine) in children, adults and elderly.

Condition Intervention Phase
Aged Biological: pneumococcal polysaccharide vaccine Phase 4

Study Type: Interventional
Study Design: Intervention Model: Parallel Assignment
Masking: None (Open Label)
Official Title: A Study of Evaluation Indexes for Antibody Production in Sera After Immunization

Resource links provided by NLM:


Further study details as provided by Ewha Womans University:

Primary Outcome Measures:
  • Evaluate the immune response to the pneumococcal polysaccharide vaccine in children, young adults and elderly. [ Time Frame: 1 month after vaccination ]

Secondary Outcome Measures:
  • Evaluate the immune response to the pneumococcal polysaccharide vaccine with two methods (ELISA and Opsonophagocytic Killing Assay) [ Time Frame: 1 month after vaccination ]

Enrollment: 70
Study Start Date: April 2005
Study Completion Date: June 2005
Primary Completion Date: May 2005 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Pneumococcal polysaccharide vaccine
The immunogenic response to the pneumococcal polysaccharide vaccine was compared between children, adults and elderly.
Biological: pneumococcal polysaccharide vaccine
single intramuscular injection of 0.5 ml Pneumo23® (Sanofi-Aventis, Lyon France)
Other Name: Pneumo23®

Detailed Description:
To evaluate the immune response to the pneumococcal polysaccharide vaccine in the elderly, samples from children, young adults and elderly were obtained before and one month after vaccination. The quantitative and qualitative response to the vaccine were measured by the ELISA and opsonophagocytic killing assay for eight vaccine type serotypes (4, 6B, 9V, 14, 18C, 19A, 19F, 23F) and one vaccine-related serotype (6A).
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   2 Years to 90 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • elderly subjects over the age 65 years who had not received pneumococcal vaccination
  • adult subjects under the age of 45 years (healthy volunteers with no previous history of pneumococcal vaccination)
  • children subjects over the age of 2 years with no previous history of pneumococcal vaccination

Exclusion Criteria:

  • immunocompromised, asplenia, cancer, liver or renal failure, and history of hypersensitivity to vaccine
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00964769


Locations
Korea, Republic of
Ewha Womans University Dongdaemun Hospital
Seoul, Korea, Republic of, 110-125
Sponsors and Collaborators
Ewha Womans University
Investigators
Principal Investigator: Kyung-Hyo Kim, Doctor Ewha Womans University Dongdaemun Hospital
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Kyung-Hyo Kim, Ewha Womans Univrsity Hospital
ClinicalTrials.gov Identifier: NCT00964769     History of Changes
Other Study ID Numbers: EU-KF-05092341
05092KFDA341
First Submitted: August 24, 2009
First Posted: August 25, 2009
Last Update Posted: August 25, 2009
Last Verified: August 2009

Keywords provided by Ewha Womans University:
Pneumococcal Vaccine
Aged

Additional relevant MeSH terms:
Vaccines
Antibodies
Heptavalent Pneumococcal Conjugate Vaccine
Immunologic Factors
Physiological Effects of Drugs